Table 1.

Characteristics of patients and a summary of survey responses.

Total number of patients invited to enroll in the study, N	572
Total number of patients who completed survey, N (survey response rate)	525 (91.8%)
Final analytic sample, excluding patients with no fasting labs (127) and patients with incomplete data (35)	363
Mean age (SD), years	60.6 (12.5)
Mean diabetes duration (SD), years	16.0 (11.5)
Sex, female	194 (53.2%)
Patients reporting type 2 diabetes mellitus, N (%)	298 (81.6%)
Patients on hypoglycemia-inducing OHAs∗ (without insulin)	36
Patients on insulin without hypoglycemia-inducing OHAs	215
Patients on both insulin and hypoglycemia-inducing OHAs	18
Total at-risk patients for FEEHD∗∗	269 (74.1%)
Total patients with FEEHD∗∗∗	62 (17.1%)
Patients with FEEHD from “at-risk” patient group (prevalence)	59 (21.9%)∗∗∗∗
Multiple FEEHD episode patients	7
Patients educated by health care prior to fasting labs	131 (35.9%)

FEEHD = fasting-evoked en route hypoglycemia in diabetes; SD = standard deviation; OHA = oral hypoglycemic agent. ^∗Sulfonylureas and meglitinide analogues. ^∗∗At-risk patients: patients who had fasting labs done and were on insulin or hypoglycemia-inducing OHAs or both. ^∗∗∗FEEHD: fasting-evoked en route hypoglycemia in diabetes. ^∗∗∗∗3 patients who had FEEHD were not on any hypoglycemia-inducing OHA or insulin. They were on metformin, saxagliptin, liraglutide, or canagliflozin.